For noninfectious diarrhea in adults living with HIV/AIDS who are on ART*

Mytesi Savings Programs

It is Napo Pharmaceuticals’ goal to get Mytesi into the hands of any person living with HIV who needs it. The Mytesi Copay Savings Card and the NapoCares™ Patient Assistance Program have been created to help achieve this goal.

Mytesi Copay Savings Card
Pay no more than $25
on your Mytesi prescriptions, with max
benefit of $100 on each prescription

Click here to save today

The Mytesi Savings Card gives eligible patients savings of up to $1,200 per year in copay assistance for Mytesi

Subject to eligibility. Restrictions apply.

NapoCares™ Patient Assistance Program

Napo Pharmaceuticals is committed to helping patients overcome coverage challenges and reimbursement issues in order to optimize their treatment regimens.

Through NapoCares Patient Assistance Program (PAP), Napo Pharmaceuticals provides eligible patients access to Mytesi at no cost. To apply for participation in NapoCares PAP: Download and complete the NAPOCARES PAP APPLICATION.

Additionally, Napo provides support in the following areas:

•   Benefit Verification

•   Prior Authorization

•   Claims Appeals

If you are experiencing challenges securing coverage for Mytesi through prior authorizations, receiving rejected claims, or if you have additional questions regarding NapoCares Patient Assistance Program (PAP), please contact us at:

Napo Pharmaceuticals, Inc.

NapoCares Patient Assistance Program

P.O. Box 259

Acworth, GA 30101-0259

Phone: (888) 527-NAPO (6276)

Fax: (866) 468-2420

Email: NapoCares@medcommtech.com

Monday-Friday 8 AM – 5 PM EST

Call (888) 527-NAPO (6276)
 for more information

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

For product information, adverse event reports, and product complaint reports, please contact: 
Napo Pharmaceuticals     
email: napopharma@missionpharmacal.com        
phone: (844) 722-8256

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

For product information, adverse event reports, and product complaint reports, please contact: 
Napo Pharmaceuticals     
email: napopharma@missionpharmacal.com        
phone: (844) 722-8256

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

©2016 Napo Pharmaceuticals Inc. All rights reserved.

350a-g-1

  • *Indication

    MYTESI™ is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI.

    If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information

  • *Indication

    MYTESI™ is an anti-diarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

    Important Safety Information about MYTESI

    MYTESI™ is not indicated for the treatment of infectious

    diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

    Click to Read Full Prescribing Information